Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-12-20

Clinical Trial Update: The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 trial exploring teriflunomide plus danazol for steroid-resistant/relapsed immune thrombocytopenia is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Danazol (danazol)
  • Teriflunomide (teriflunomide)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN